Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Sponsor
- Abbott
- Study ID
- NCT00645814
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- placebo for adalimumab — DRUG80 mg at Week 0 and 40 mg eow through Week 11
- adalimumab — DRUG80 mg at Week 0 and 40 mg eow through Week 11
- adalimumab — DRUG80 mg at Week 0 and 40 mg weekly through Week 11
Study Details
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Key Dates
- Start date
- Mar 31, 2003
- Status verified
- Mar 2008
- Primary completion
- Sep 30, 2003
Study Design
- Enrollment
- 148 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: A
- Active Comparator: B
- Active Comparator: C
Primary Outcome Measure
Psoriasis Area and Severity Index [ Time Frame: Week 12 ]
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Regulation of Inflammatory Genes in PsoriasisRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisEnrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
- An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis PatientsRecruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey